Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of novel small molecule compounds with readthrough activity in Nagashima-type palmoplantar keratosis.

Journal of dermatological science - 1 Jun 2026

Peh Jin Teng, Sugiyama Takato, Nobuta Risa, Miyauchi Toshinari, Suzuki Shotaro, Takeda Masae, Ohguchi Yuka, Ujiie Hideyuki, Nomura Toshifumi

Abstract excerpt

BACKGROUND: Nagashima-type palmoplantar keratosis (NPPK), the most common form of hereditary palmoplantar keratodermas in East Asian populations, is caused by biallelic loss-of-function mutations in SERPINB7 such as p.Arg266Ter (c.796 C>T). This mutation introduces a premature termination codon (PTC). Given the minimal efficacy of current drugs in improving NPPK skin phenotypes, we applied readthrough therapy to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Codon, Nonsense

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gentamicins

Share to High-Throughput Screening Assays

Share to Keratoderma, Palmoplantar

Share to Oxadiazoles

Share to Ribosomes

Share to Serpins

Source

Identifiers

PMID: 42034525
DOI: 10.1016/j.jdermsci.2026.02.001

Genes

SERPINB7

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of novel small molecule compounds with readthrough activity in Nagashima-type palmoplantar keratosis.PMID 42034525Read ↗

Gentamicin-Induced Readthrough and Nonsense-Mediated mRNA Decay of SERPINB7 Nonsense Mutant Transcripts.Semantic proximity Read ↗

Genome-scale quantification and prediction of pathogenic stop codon readthrough by small moleculesSemantic proximity Read ↗

A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletionSemantic proximity Read ↗

Small molecule Y-320 stimulates ribosome biogenesis, protein synthesis, and aminoglycoside-induced premature termination codon readthrough.Semantic proximity Read ↗

Readthrough compounds for nonsense mutations: bridging the translational gap.Semantic proximity Read ↗

Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs).Semantic proximity Read ↗

Effect of Readthrough Treatment in Fibroblasts of Patients Affected by Lysosomal Diseases Caused by Premature Termination Codons.Semantic proximity Read ↗

Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination CodonsSemantic proximity Read ↗

Aminoglycoside-induced premature termination codon readthrough of <i>COL4A5</i> nonsense mutations that cause Alport syndromeSemantic proximity Read ↗

Ataluren: first global approval.Semantic proximity Read ↗

Therapeutic suppression of premature termination codons: mechanisms and clinical considerations (review).Semantic proximity Read ↗

Novel small molecules potentiate premature termination codon readthrough by aminoglycosides.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.